Fortrea Holdings (FTRE) EBITDA (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly EBITDA came in at $14.8 million in Q2 2026, up 104.48% on a YoY basis from $7.2 million in Q2 2025, and up 535.29% quarter-over-quarter from -$3.4 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) EBITDA (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has reported EBITDA for 5 consecutive years, with $14.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA rose 104.48% year-over-year to $14.8 million; the trailing twelve-month figure through Jun 2026 stood at -$10.8 million (up 98.83% YoY), and the FY2025 full-year result was -$852.9 million, down 520.74% from the prior year.
- EBITDA improved to $14.8 million in Q2 2026 per FTRE's latest filing, from -$3.4 million in the prior quarter.
- Across five years, EBITDA topped out at $71.2 million in Q2 2022 and bottomed at -$520.1 million in Q1 2025.
- Historically, EBITDA has averaged -$49.2 million across 5 years, with a median of -$8.6 million in 2025.
- The sharpest annual moves came in 2025 and 2026: EBITDA sank 1290.64% in 2025, then jumped 104.48% in 2026.
- Over 5 years, EBITDA stood at $14.3 million in 2022, then slumped by 267.83% to -$24.0 million in 2023, then tumbled by 131.67% to -$55.6 million in 2024, then surged by 75.54% to -$13.6 million in 2025, then jumped by 208.82% to $14.8 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered $14.8 million, -$3.4 million, and -$13.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.06 Bn | 42.11 Bn | 1.44 Bn | 506.00 Mn |
| 2 | Medpace Holdings | 16.50 Bn | 16.00 Bn | 201.64 Mn | 153.38 Mn |
| 3 | Charles River Laboratories International | 13.77 Bn | 13.62 Bn | 452.07 Mn | 119.89 Mn |
| 4 | Icon | 12.62 Bn | 11.69 Bn | 479.29 Mn | 327.25 Mn |
| 5 | Fortrea Holdings | 1.68 Bn | 1.51 Bn | 139.20 Mn | 14.80 Mn |
| 6 | Evotec SE | 661.34 Mn | 235.46 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 442.79 Mn | 358.26 Mn | 18.44 Mn | -58.55 Mn |
| 8 | Champions Oncology | 72.49 Mn | 72.62 Mn | 7.03 Mn | -522,000.00 |
| 9 | MindWalk Holdings | 61.66 Mn | 53.38 Mn | 1.82 Mn | -2.33 Mn |
| 10 | VivoSim Labs | 1.47 Mn | 1.47 Mn | - | -2.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.80 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -13.60 Mn |
| Sep 30, 2025 | -8.60 Mn |
| Jun 30, 2025 | -330.30 Mn |
| Mar 31, 2025 | -520.10 Mn |
| Dec 31, 2024 | -55.60 Mn |
| Sep 30, 2024 | -18.00 Mn |
| Jun 30, 2024 | -50.90 Mn |
| Mar 31, 2024 | -37.40 Mn |
| Dec 31, 2023 | -24.00 Mn |
| Sep 30, 2023 | 10.30 Mn |
| Jun 30, 2023 | 31.60 Mn |
| Mar 31, 2023 | 14.10 Mn |
| Dec 31, 2022 | 14.30 Mn |
| Sep 30, 2022 | 68.90 Mn |
| Jun 30, 2022 | 71.20 Mn |